Compare ADMA Biologics Inc (ADMA) vs Futu Holdings Ltd (FUTU) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

FUTU trades at $94.03, down 1.06% on the day, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $22.85B in 2025 and a net income margin of 41.83%, but faces multiple securities class action lawsuits alleging fraud related to undisclosed regulatory penalties. Valuation ratios appear attractive with a P/E of 10.85 and EV/EBITDA of 7.16.

The outlook is clouded by legal risks and mixed earnings performance, with recent misses on EPS estimates. Analyst consensus remains positive with 58% buy ratings, but investors must weigh solid fundamentals against significant litigation overhangs and regulatory scrutiny that could impact future performance.